Ironwood Pharmaceuticals (IRWD) PT Lowered to $17 at BTIG

Go back to Ironwood Pharmaceuticals (IRWD) PT Lowered to $17 at BTIG

UPDATE: Credit Suisse Downgrades Ironwood Pharmaceuticals (IRWD) to Neutral

November 7, 2018 5:15 AM EST

(Updated - November 7, 2018 7:56 AM EST)

(updated to add analyst comments)

Credit Suisse analyst Vamil Divan downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Outperform to Neutral with a price target of $14.00 (from $22.00) citing disappointing updates on key product Linzess and what... More

JPMorgan Downgrades Ironwood Pharmaceuticals (IRWD) to Underweight

November 7, 2018 5:10 AM EST

JPMorgan analyst Eric Joseph downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Neutral to Underweight with a price target of $11.00 (from $20.00).

For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.

Shares of Ironwood Pharmaceuticals closed at $12.78 yesterday.

... More